About Us

Our Story


Benu BioPharma is a biopharmaceutical development management and consulting company. Benu BioPharma is focused on providing the essential functional expertise for drug development with the efficiency, nimbleness and speed that is critical to success for an entrepreneurial organization. The company is based in Natick, Massachusetts.

Benu is a unique venture model based on active partnership of experienced drug developers. Benu takes an asset-based approach where each new product-focused company becomes an individual investment. We believe that academic and biotechnology centers in Boston and southern New England are great engines for novel, product focused technologies around which we build our companies. Benu benefits from decades of experience utilizing the virtual company model and builds upon existing projects, both of which received funding in 2012.

2012-2017 Virtual biotechnology companies managed by Benu BioPharma


LipimetiX Development, LLC -Apolipoprotein E mimetic peptide for Homozygous Familial Hypercholesterolemia (HoFH), coronary artery and peripheral artery diseases in preclinical development. The lead peptide was extensively validated in the most relevant animal models by a leading academic institution prior to formation of the company. >> Visit LipimetiX Development

eXIthera Pharmaceuticals, Inc - A clinical stage biotech company focused on discovering and developing effective anticoagulants/antithrombotics without increased bleeding risk or the need for a reversal agent. eXithera presented the results of a Phase 1a/1b clinical study of EP-7041, as novel, small molecule Factor Xia inhibitor at the 2017 AHA Scientific Sessions. >> Visit eXIthera Pharmaceuticals

Topical Remedy, LLC -Novel topical drug formulation for the treatment of herpes labialis, suitable for the OTC market. Topical Remedy is currently in Phase 2 clinical trials.

News and Events

November 14, 2017

eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
>> Read More

December 19, 2016

Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
>> Read More

Aug. 25, 2016

Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc.
>> Read More

Feb. 03, 2016

Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period Other OTC_CAPS
>> Read More

Dec. 15, 2015

Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period Other OTC_CAPS
>> Read More

Oct. 14, 2015

Capstone Therapeutics Announces Allowance of U.S Patent for Treatment of Diabetes with Apo E Mimetic Peptides
>> Read More